Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023
Frontiers in Public Health · 22.04.2026 · 14
DOI: 10.3389/fpubh.2026.1808528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 22.04.2026. Verfasst von Janet M Grubber und 7 weiteren Autor:innen. Beteiligte Einrichtung: VA Cooperative Studies Program, Boston, MA, United States. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Influenza, Human, COVID-19, Coinfection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Routine testing for SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) was deployed in a large US healthcare system in 2022–2023. This policy allowed identification of a large cohort of co-infected patients and comparison of outcomes without confounding by testing indication.
Methods
Patients “triple-tested” in the US Veterans Health Administration were classified by infection status in the first week of a positive test. Multivariable logistic regression was used to estimate associations of different infections with hypoxemia (SpO 2 < 90% or supplementary oxygen >2 L/min) or death, separately, expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI).
Findings
Among 835,987 triple-tested patients, 170,592 (20.4%) tested positive for SARS-CoV-2 alone, 30,454 (3.6%) influenza alone, 13,207 (1.6%) RSV alone, and 1,300 (0.2%) multiple viruses. Frequencies of hypoxemia and death were 8.0 and 1.9% with SARS-CoV-2, 7.7 and 0.8% with influenza, 9.3 and 1.1% with RSV, 8.7 and 1.5% with multiple viruses, and 8.9 and 2.0% with all-negative tests. After adjustment for age and immune-suppressive drugs, odds of hypoxemia were slightly higher with influenza (aOR = 1.12, CI 1.06–1.17), lower with RSV (aOR = 0.91, CI 0.85–0.97), and not significantly different with multiple viruses (aOR = 1.09, CI 0.89–1.34), relative to SARS-CoV-2 alone. Odds of death were lower with influenza (aOR = 0.52, CI 0.46–0.60) or RSV (aOR = 0.51, CI 0.43–0.60) and no different with multiple infections (aOR = 0.86, CI 0.54–1.36), relative to SARS-CoV-2 alone.
Interpretation
Co-infection was rare (0.2% of tested cases), with incidences of hypoxemia and death similar to SARS-CoV-2 alone. Death was less frequent with influenza or RSV than SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- VA Cooperative Studies Program, Boston, MA, United States.
- VA Boston Healthcare System, Boston, MA, United States.
- Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
- Veterans Affairs North Texas Health Care System, Dallas, TX, United States.
- Harvard Medical School, Boston, MA, United States.
- School of Medicine, Boston University, Boston, MA, United States.
Zitieren
APA
Grubber, J. M., Oboho, I. K., Swinnerton, K. N., Feldman, T. C., Do, N. V., Fillmore, N. R., Branch-Elliman, W., & Monach, P. A. (2026). Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1808528
Vancouver
Grubber JM, Oboho IK, Swinnerton KN, Feldman TC, Do NV, Fillmore NR, et al. Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1808528
BibTeX
@article{Grubber2026,
author = {Grubber, Janet M and Oboho, Ikwo K and Swinnerton, Kaitlin N and Feldman, Theodore C and Do, Nhan V and Fillmore, Nathanael R and Branch-Elliman, Westyn and Monach, Paul A},
title = {Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022–2023},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1808528}
}
EUVIMED